Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415725 | 1.00 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2LMNASYK | |
| SCHEMBL5416681 | 0.92 | SYK (0.41) | TAS1R3TAS1R1TAS1R2LMNASYK | |
| SCHEMBL5422332 | 0.92 | SYK (0.41) | TAS1R3TAS1R1TAS1R2LMNASYK | |
| SCHEMBL5423507 | 0.91 | LMNA (0.36) | LMNASYKSMN1; SMN2ALDH1A1 | |
| SCHEMBL5416023 | 0.91 | LMNA (0.36) | LMNASYKSMN1; SMN2ALDH1A1 | |
| SCHEMBL5423373 | 0.89 | ALDH1A1 (0.39) | LMNASYKSMN1; SMN2ALDH1A1 | |
| SCHEMBL5413956 | 0.89 | ALDH1A1 (0.39) | LMNASYKSMN1; SMN2ALDH1A1 | |
| Hexamethylbenzene SCHEMBL5418276 | 0.88 | LMNA (0.35) | LMNASMN1; SMN2ALDH1A1 | |
| Hexamethylbenzene SCHEMBL5418228 | 0.88 | LMNA (0.35) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5418209 | 0.87 | ALDH1A1 (0.43) | LMNASMN1; SMN2TP53CASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268250-B2 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20040176616-A1 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176616-A1 | Process for producing optically active compound | OSTC, NPEPPS, PPOX | TAS1R3 4506/4885TAS1R1 4559/4885TAS1R2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.